Research Labs: Martin Markowitz, M.D.
Curriculum Vitae

Scientific Overview
Non-Scientific Summary

Dr. Martin Markowitz:
   CV
   Personnel
   Publications

Return to Research Programs

Name: Martin Markowitz, M.D.

Education:

1970-1974 B.A., Biology, State University of New York at Buffalo, Buffalo, New York
1974-1978 M.D. Stanford University School of Medicine, Stanford, California

Internship and residency:

1978-1979 Internship, Medicine, Mount Zion Hospital and Medical Center, University of California, San Francisco, San Francisco, CA
1979-1981 Residency, Medicine, Mount Zion Hospital and Medical Center, University of California, San Francisco, San Francisco, CA
   
Fellowship training:
1981-1982 Clinical Fellow, Hematology/Oncology, Cornell Medical College, New York, NY
1982-1983 Research Fellow, Hematology/Oncology, Cornell Medical College, New York, NY
1991-1992 Clinical Fellow, Division of Infectious Diseases, NYU/Bellevue, New York, NY
1992-1994 Research Fellow, Aaron Diamond AIDS Research Center, New York, NY
   
Clinical appointments:
1983-1984
 Chief Clinical Fellow, Instructor, Dept. of Medicine, Div. Hematology/Oncology Cornell Medical Center
1985
 Assistant Attending Physician, Hospital for Special Surgery
1986
 Attending Adult Hematologist, Regional Comprehensive Hemophilia Diagnostic and Treatment Center, Cornell Medical College
1985-1989
 Attending Hematologist/Oncologist, Spellman Center for the Treatment of HIV Related Disease, St. Clare's Hospital, New York, NY
1989
 Acting Director, Spellman Center, St. Clare's Hospital, New York, NY
1985-1990 Attending Staff, Dept. of Medicine, Lenox Hill Hospital, Div. Hematology/Oncology, New York, NY
1995-1996
 Visiting Associate Physician, Rockefeller University Hospital, Rockefeller University Hospital, New York, NY
1996-present
 Adjunct Associate Physician, Cornell Medical College, Division of Infectious Diseases. New York, NY
1996-present
 Associate Physician, Rockefeller University Hospital, New York, NY
 
Academic Appointments
1984-1985 Instructor, Dept. of Medicine/Div. Hematology/Oncology, Cornell Medical College
1994-1995 Instructor, Department of Medicine, New York University
1995-1996 Assistant Professor, Department of Medicine, Division of Infectious Diseases, New York University Medical School, New York, New York
1994-present Staff Investigator, Aaron Diamond AIDS Research Center
1998-present Clinical Director, Aaron Diamond AIDS Research Center
2000-present Associate Professor of Clinical Investigation, The Rockefeller University, New York, New York
   

Committee Assignments and Board Membership:
1997-Present Scientific Advisory Board, GlaxoSmithKline
1997-2000 Scientific Advisory Board, Agouron Pharmaceuticals
1998-Present Scientific Advisory Board, Merck & Company
1998-2003 Scientific Advisory Board, Bristol-Myers Squibb
1998 Review Committee, National Cancer Institute, Developmental Therapeutics Program
1998-2002 Director, Clinical Core, Columbia University-Rockefeller University Center for AIDS Research
1998-2003 American Foundation for AIDS Research (amfAR), Scientific Grants Review
1998-2002 Editor, AIDS Treatment Report, amfAR
1998-Present Editorial Board, Physicians Research Network
1999-2002 Board of Directors, Mothers Voices (to end AIDS)
1999-2002 Editorial Board, Thrive Magazine, Los Angeles, California
1999-2001 Scientific Advisory Board, Structured Treatment Interruption Workshop Committee
2000-Present Associate Editor, Journal of AIDS
2000-2003 Scientific Advisory Board, Triangle Pharmaceuticals
2001-Present Scientific Advisory Board, Gilead Sciences
2001-2004 Scientific Advisory Board, Boehringer Ingelheim
2001-Present NIH Study Section- Special Emphasis Panel, HIV/AIDS
2001-2004 Kenya AIDS Watch Institute (KAWI), Advisor to Board of Directors
2001-2002

Vice-chair Acute Infection Early Disease Research Program (AIEDRP)Executive Committee

2002-2003 Chair, Acute Infection Early Disease Research Program (AIEDRP) Executive Committee
2002-2003 Director, Virology Core, Columbia University-Rockefeller University Center for AIDS Research
2003-Present Member, Acute Infection Early Disease Research Program (AIEDRP) Executive Committee
2002-2003

Member, General Clinical Research Center Advisory Committee,Rockefeller University

2002-Present

Consultant, Indiana University/Moi University School of Medicine CIPRA Program, Eldoret, Kenya
2002-2005 Member, UN Millennium Project Task Force on HIV/AIDS, TB, Malaria and Access to Essential Medicines
2003-2004 Member, The Rockefeller University Hospital Institutional Review Board
2003-Present Scientific Advisor, Campbell Foundation, Fort Lauderdale, FL
2004-Present Member, Scientific Advisory Board, Sequoia Pharmaceuticals
2005-Present Member, Experimental Therapeutics Research Agenda Committee (ET RAC), ACTG             (Renamed Translational Research and Drug Development {TRADD} as of 2006)
2006-Present Volunteer Physician Panelist - AIDS Educations Global Information System (AEGIS) 
2006-Present Chair, Data Safety Monitoring Board (DSMB), Panacos Pharmaceuticals
   

Protocol Activities:
2003-Present Protocol Chair, CORE01/ACTG 5228 – Acute HIV Infection and Early Research Program (AIEDRP)
2004-Present Protocol Chair, AIN501/ACTG 5216 – A Randomized Phase II Study of the Safety, Immunologic and Virologic Effects of Cyclosporine A in Conjunction with Trizivir and Kaletra versus Trizivir and Kaletra Alone during Primary HIV-1 Infection.
2004-Present Protocol Virologist, AIN503/ACTG 5217 – A Randomized Study of Treatment with Tenofovir DF, Emtricitabine, and Lopinavir/Ritonavir versus no Therapy in Newly Infected HIV-1 Infected Subjects to Determine Whether Potent Antiretroviral Therapy Alters the Virologic Setpoint.  
   

Certification:

  Board Certification: Internal Medicine (1981)
  Hematology (1984)
  Medical Oncology (1983)
   
Board Eligibility:
  Infectious Diseases
   

Honors:

 Phi Beta Kappa
   

Awards:

  
  AmFAR Award of Courage, New York, New York. 6/2001
  Honoree: 10th Annual Mothers' Voices 10/2001
   
Memberships:  
  American Society of Microbiology
  Infectious Disease Society of America
   
Editor: Journal of AIDS
   
Review assignments:
  Journal of the American Medical Association
  Journal of Virology
  Lancet
  Journal of Infectious Diseases
  AIDS and Human Retroviruses
  PNAS
  AIDS after PNAS
   

Peer reviewed publications:

  1. Feigert, J., Sweet, D., Coleman, M., Variakojis, D., Wisch, N., Schulman, J., and Markowitz, M. 1990. Multicentric angiofollicular lymph node hyperplasia with peripheral neuropathy, pseudotumor cerebrii, IgA dysproteinemia and thrombocytosis in women. Ann. Intl. Med. 113 (5): 362-367
    [view]
  2. Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M., and Markowitz, M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126. [view]
  3. Markowitz, M., Mo, M., Kempf, D., Norbeck, D., Bhat, T., Erickson J.W., and Ho. D.D. 1995. Selection and analysis of HIV-1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69(2): 701-706. [view]
  4. Markowitz, M., Saag, M., Powderly, W., Hurley, A., Hsu, A., Valdes, J., Henry, D., Sattler, F., LaMarca, A., Leonard, J.M., and Ho. D.D. 1995. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Eng. J. Med. 333:1534-1539. [view]
  5. Mo, H., Markowitz, M., Majer, P., Burt, S.K., Gulnik, S., Erickson, J.W., and Ho, D.D. 1996. Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease. AIDS Res. Hum. Retroviruses 12 (1): 55-61. [view]
  6. Patick, A., Mo, H., Markowitz, M., Appelt, K., Wu, B., Musik, L., Kalish, V., Kaldor, S., Reich, S., Ho, D., and Webber, S. 1996. Antiviral activity and resistance studies of AG1343, an orally bioavailable inhibitor of HIV-1 protease. Antimicrobial Agents and Chemother. 40 (2): 292-297. [view]
  7. Perelson, A., Neumann, A.U., Markowitz, M., Leonard, J.M., and Ho, D.D. HIV-1 Dynamics in Vivo: Virion clearance rate, infected cell life span, and viral generation time. Science 271:1582-1586. [view]
  8. Molla, A., Korneyeva, M., Gao, Q., Vasavanonda, S. Schipper, P.J., Mo, H., Markowitz, M., Chernyavskty, T., Niu, P., Lyons, N., Hsu, A., Granneman, G.R., Ho, D.D., Boucher, C.A.B., Leonard, J.M., Norbeck, D.W., and Kempf, D. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2: 760-766. [view]
  9. Perelson, A.S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K., Markowitz, M., and Ho D.D. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387: 188-191. [view]
  10. Binley, J.M., Klasse, P.J., Cao, Y., Jones, I., Markowitz, M., Ho, D.D., and Moore. J.P. 1997. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J. Virol. 71: 2799-2809. [view]
  11. Poppe, S.M., Slade, D.E., Chong, K.T., Hinshaw, R.R., Pagano, P.J., Markowitz, M., Ho, D.D., Gorman III, R.R., Dueweke, T.J., Thaisrivongs, S., and Tarpley, W.G. 1997. Antiviral activity of the dihydropyrone PNU-140690, a new non-peptidic human immunodeficiency virus protease inhibitor. Antimicrobial Agents and Chemother. 41: 1058-1063. [view]
  12. Vesanen, M., Markowitz, M., Cao, Y., Ho, D.D., and Saksela, K. 1997. Human immunodeficiency virus Type-1 mRNA splicing patterns in infected persons is determined by the proportion of newly infected cells. Virology 236: 104-109. [view]
  13. Finzi, D., Hermankova, M., Pierson, T., Carruth, L.M., Buck, C., Chaisson, R.E., Quinn, T.C., Chadwick, K., Margolick, J., Brookmeyer, R., Gallant, J., Markowitz, M., Ho, D.D., Richman, D.D., and Siliciano, R.F. 1997. Identification of a reservoir for HIV-1 infected-patients on highly active antiretroviral therapy. Science. 278: 1295-1300. [view]
  14. Delwart, E., Pan, H., Neumann, A., and Markowitz, M. 1998. Rapid, transient changes at the env locus of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance. J. Virol. 72: 2416-2421. [view]
  15. Markowitz, M., Conant, M., Hurley, A., Schluger, R., Duran, M., Peterkin, J., Chapman, S., Patick, A., Hendricks, A., Yuen, G.J., Hoskins, W., Clendennin, N, and Ho, D.D. 1998. A preliminary evaluation of nelfinavir meyslate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J.Inf.Dis. 177:1533-1540. [view]
  16. Eastman, P.S., J. Mittler, R.Kelso, C. Gee, E. Boyer, J. Kolberg, M. Urdea, J.M. Leonard, D. W. Norbeck, H. Mo, and M. Markowitz. 1998. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J. Virol. 72: 5154-5164. [view]
  17. Morris, L., Binley, J.M., Clas, B.A., Bonhoeffer, S., Astill, T.P., Kost, R., Hurley, A., Cao, Y., Markowitz, M., Ho, D.D., and Moore, J.P. 1998. HIV-1 antigen-specific and - nonspecific B cell responses are sensitive to combination antiretroviral therapy. J. Exp. Med. 188: 233-245. [view]
  18. Boden, D., and Markowitz, M. 1998. Resistance to human immunodeficiency virus type-1 protease inhibitors. Antimicro. Agents Chemother. 42: 2775-2783. [view]
  19. Ogg, G. S., Jin, X., Bonhoeffer, S., Dunbar, P. R., Nowak, M.A., Monard, S., Segal, J. P., Cao, Y., Rowland-Jones, S. L., Cerundolo, V., Hurley, A. Markowitz, M., Ho, D. D., Nixon, D. F., and McMichael, A. J. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of RNA. Science 279(5359): 2103-2106. [view]
  20. Patick, A.K., Duran, M., Cao, Y., Shugarts, D., Keller, M.R., Mazabel, E., Knowles, M., Chapman, S., Kuritzkes, D.R., and Markowitz, M. 1998. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicro. Agents Chemother. 42: 2637-2644. [view]
  21. Ogg, G.S., Jin. X., Bonhoeffer, S., Moss, P., Nowak, M.A., Monard, S., Segal, J.P., Cao, Y., Rowland-Jones, S.L., Hurley, A., Markowitz, M., Ho, D.D., McMichael, A.J., and Nixon, D.F. 1999. Decay kinetics of human immunodeficiency virus specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J. Virol. 73: 797-800 [view]
  22. Cameron, D.W., Japour, A.J., Xu, Y., Hsu, A., Mellors, J., Farthing, C., Cohen, C., Poretz, D., Markowitz, M., Follansbee, S., Angel, J.B., McMahon, D., Ho, D., Devanarayan, V., Rode, R., Salgo, M.P., Kempf, D.J., Granneman, R., Leonard, J.M, and Sun, E. 1999. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 13: 213-224. [view]
  23. Markowitz, M., Vesanen, M., Tenner-Racz, K., Cao, Y., Binley, J.M., Talal, A., Hurley, A., Jin, X., Chaudhry, M.R., Yaman, M., Frankel, S., Heath-Chiozzi, M., Leonard, J.M., Moore, J.P., Racz, P., Nixon, D.F., and Ho, D.D. 1999. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type-1 infection on viral replication and antiviral immune responses. J. Infect. Dis. 179: 527-537. [view]
  24. Nixon, D.F., Douek, D., Kuebler, P.J., Jin, X., Vesanen, M., Bonhoeffer, S., Cao, Y., Koup, R.A., Ho, D.D., and Markowitz, M. 1999. Molecular tracking of a human immunodeficiency virus nef specific cytotoxic T-cell clone shows persistence of clone-specific T-cell receptor DNA but not mRNA following early combination antiretroviral therapy. Immunol. Letters. 66: 219-228. [view]
  25. Lewin, S.R., Vesanen, M., Kostrikis, L., Hurley, A., Duran, M., Zhang, L., Ho, D.D., and Markowitz, M. 1999. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1 infected individuals on prolonged effective antiretroviral therapy. J. Virol. 73: 6099-6103. [view]
  26. Zhang, L., Ramratnam, B., Tenner-Racz, K., He, Y., Vesanen, M., Lewin, S., Talal, A., Racz, P., Perelson, A.S., Korber, B.T., Markowitz, M., and Ho, D.D. 1999. Quantifying residual HIV-1 replication in-patients receiving combination antiretroviral therapy. N. Eng. J. Med. 340: 1605-1613. [view]
  27. Ramratnam, B., Bonhoeffer, S., Binley, J., Hurley, A., Zhang, L., Mittler, J.E., Markowitz, M., Moore, J.P., Pereleson, A.S., and Ho, D.D. 1999. Rapid production and clearance of HIV-1 and hepatitis C virus particles in infected individuals as defined by large volume plasma apheresis. Lancet 354: 1782-1785 [view]
  28. Boden, D., Hurley, A., Zhang, L., Cao, Y., Guo, Y., Jones, E., Tsay, J., Ip, J., Farthing, C., Limoli, K., Parkin, N., and Markowitz, M. 1999. Prevalence of HIV-1 drug resistance in 80 newly infected individuals. JAMA 282: 1135-1141 [view]
  29. Zhang, L., Lewin, S.R., Markowitz, M., Lin, H. H., Skulsky, E., Karanicolas, R., He, Y., Jin, X., Tuttleton, S., Vesanen, M., Spiegel, H., Kost, R., van Lunzen, J., Stelbrink, H. J., Wolinsky, S., Borkowsky, W., Palumbo, P., Kostrikis, L. G., and Ho, D.D. 1999. Measuring recent thymic emigrants in blood of normal persons and HIV-1-infected patients before and after effective therapy. J. Exp. Med. 190: 725-732. [view]
  30. Mittler, J. E., Markowitz, M., Ho, D. D., Perelson, A. S. 1999. Improved estimates for HIV-1 clearance rate and intracellular delay. AIDS. 13 (11): 1415-1417. [view]
  31. Parkin, N. T., Lie, Y. S., Hellmann, N., Markowitz, M., Bonhoeffer, S. Ho, D. D., Petropoulos, C. J. 1999. Phenotypic changes in drug susceptibility associated with the failure of human immunodeficency virus type 1 (HIV-1) triple combination therapy. J. Infect Dis. 180(3): 865-870. [view]
  32. Markowitz, M. 1999. Acute HIV-1 infection: Early identification and treatment. Amer. Fam. Phys. 60 (2): 413-418.
  33. Ortiz, G.M., Nixon, D.F., Trkola, A., Binley, J., Jin, X., Bonhoeffer, S., Kuebler, P.J., Donahoe, S.M., Demoitie, M.A., Kakimoto, W.M., Ketas, T., Clas, B., Heymann, J.J., Zhang, L., Cao, Y., Hurley, A., Moore, J.P., Ho, D.D., and Markowitz, M. 1999. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J. Clin. Invest. 104: R13-R18. [view]
  34. Binley, J.M., Schiller, D.S., Ortiz, G.M., Hurley, A., Nixon, D.F., Markowitz, M., and Moore, J.P. 2000. The relationship between T-proliferative responses and plasma viremia during treatment of HIV-1 infection with combination antiviral therapy. J. Infect. Dis. 181: 1249-1263 [view]
  35. Schiller, D.S., Binley, J.M., Roux, K.H., Adamson, C.S., Jones, I.M., Krausslich, H-G., Hurley, A., Markowitz, M., and Moore, J.P. 2000. Parameters influencing measurement of the Gag antigen-specific T-proliferative response to HIV-1 infection. AIDS Res. Hum Retroviruses 16: 259-271. [view]
  36. Markowitz, M. 2000. Resistance, fitness, adherence, and potency: mapping the paths to virologic failure. JAMA 283 (2): 250-251.
  37. Ramratnam, B., Mittler, J.E., Zhang, L., Boden, D., Hurley, A., Fang, F., Macken, C.A., Perelson, A.S., Markowitz, M., and Ho, D.D. 2000. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy. Nat. Med. 6: 82-85 [view]
  38. Smith, D., Berrey, M.M., Robertson, M., Mehrotra, D., Markowitz, M., Perrin, L., Clumeck, N., Lazzarin, A., Burckhardt, B., Weber, R., Corey, L., and Cooper, D. 2000. Virological and Immunological Effects of Combination Antiretroviral Therapy with Zidovudine, Lamivudine, and Indinavir during Primary Human Immunodeficiency Virus Type 1 Infection. J. Infect. Dis. 189: 950-954
  39. Zhang, L., Chung, C., Hu, B., He, T., Guo, Y., Kim, A.J., Skulsky, E., Jin, X., Hurley, A., Ramratnam, B., Markowitz, M., and Ho, D.D. 2000. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J. Clin. Invest. 106 (7): 839-845 [view]
  40. Jin, X., Ogg, G., Bonhoeffer, S., Safrit, J., Vesanen, M., Bauer, D., Chen, D., Cao, Y., Demoitie, M.A., Zhang, L., Markowitz, M., Nixon, D., McMichael, A., and Ho, D.D. 2000. An Antigenic Threshold for Maintaining Human Immunodeficiency Virus Type 1-specific Cytotoxic T Lymphocytes. Mol Med 6(9): 803-809
    [view]
  41. Talal, A.H., Monard, S., Vesanen, M., Zheng, Z., Hurley, A., Cao, Y., Fang, F.N., Irwin, C., Smiley, L., Johnson, J., Ho, D.D., Kost, R., and Markowitz, M.H. 2001. Virologic and immunologic effect of antiretroviral therapy on human immunodeficiency virus-1 in gut associated lymphoid tissue. JAIDS 26:1-7 [view]
  42. Kost, R.G., Hurley, A., Zhang, L., Vesanen, M., Talal, A., Furlan, S., Caldwell, P., Johnson, J., Smiley, L., Ho, D., and Markowitz, M. 2001. An open label phase II trial: amprenavir, abacavir, and zidovudine/lamivvudine in newly and chronically HIV-1-infected subjects. JAIDS 26: 332-339 [view]
  43. Mittler, J., Essunger, P., Yuen, G.J., Clendeninn, N., Markowitz, M., and Perelson, A.S. 2001. Short-Term Measures of Relative Efficacy Predict Longer-Term Reductions in Human Immunodeficiency Virus Type 1 RNA Levels following Nelfinavir Monotherapy. Antimicrob. Agents Chemother. 45: 1438-1443
  44. Mohri, H., Perelson, A.S., Tung, K., Ribeiro, R.M., Ramratnam, B., Markowitz, M., Kost, R., Hurley, A., Weinberger, L., Cesar, D., Hellerstein, M.K., and Ho, D. 2001. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J. Exp. Med. 194: 1277-1287 [view]
  45. Ortiz GM, Hu J, Goldwitz JA, Chandwani R, Larsson M, Bhardwaj N, Bonhoeffer S, Ramratnam B, Zhang L, Markowitz M., Nixon DF. 2002. Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection.J Virol. 76(1):411-5 [view]
  46. Jin X, Ramanathan M Jr, Barsoum S, Deschenes GR, Ba L, Binley J, Schiller D, Bauer DE, Chen DC, Hurley A, Gebuhrer L, El Habib R, Caudrelier P, Klein M, Zhang L, Ho DD, Markowitz M.,Salomon H. 2002. >Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Virol. 76(5):2206-16 [view]
  47. Louie M, Markowitz M., 2002. Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective. Antiviral Res. 55(1):15-25 [view]
  48. Kijak GH, Simon V, Balfe P, Vanderhoeven J, Pampuro SE, Zala C, Ochoa C, Cahn P, Markowitz M.,Salomon H. 2002. Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure. J Virol. 76(14):7000-9 [view]
  49. Zhang, L., Rowe, L., He, T., Chung, C., Yu, J., Wenjie, Y., Talal, A., Markowitz, M., and Ho., D.D. 2002. Compartmentalization of surface envelope glycoprotein of human immunodeficiency virus type 1 during acute and chronic infection. J. Virol. 76: 9465-9473 [view]
  50. Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, Parkin N, Boden D, Markowitz M. 2002. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS. 16(11):1511-9 [view]
  51. Markowitz, M., Jin, X., Hurley, A., Simon, V., Ramratnam, B., Louie, M., Deschenes, G.R., Ramanathan, M., Barsoum, S., Vanderhoeven, J., He, T., Chung, C., Murray, J., Perelson, A.S., Zhang, L., and Ho, D.D. 2002. Discontinuation of antiretroviral therapy commenced early in the course of HIV-1 infection with or without adjunctive vaccination. J Inf. Dis. 186: 634-643 [view]
  52. Ramratnam, B., Ribeiro, R., He, T., Chung, C., Simon, V., Vanderhoeven, J., Hurley, A., Zhang, L., Perelson, A.S., Ho, D.D., and Markowitz, M. 2002. Intensification of antiretroviral therapy accelerates the decay of the latent reservoir of HIV-1 and decreases but does not eliminate ongoing virus replication. J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):33-7. [view]
  53. Angel, J.B., Cameron, D.W., Jiang, P.X., Xu, Y., Rode, R., Cohen, C., Mellors, J., Farthing, C., Poretz, D., Markowitz, M., Ho, D., McMahon, D., Drennan, D., Selness, K., Sun, E., Ryan, J., and Japour, A.J. 2002. Ritonavir and saquinqvir combination therapy for the treatment of HIV infection: 3-year follow-up. AIDS. (In press).
  54. Louie, M., Hogan, C., Di Mascio, M., Hurley, A., Simon, V., Rooney, J., Ruiz, N., Brun, S., Sun, E., Perelson, A., Ho, D., and Markowitz, M. 2003. Determining the relative efficacy highly active antiretroviral therapy. J Inf. Dis. 187: 896-900 [view]
  55. Markowitz M., Louie, M., Di Mascio M., Sun, E., Perelson A., Ho, D.D. 2003. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J. Virol. 77(8): 5037-5038 [view]
  56. Percus, J.K., Percus, O.E., Markowitz, M., Ho, D.D., Di Mascio, M., and Perelson, A.S. 2003. The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy. Bull. Math. Bio. 65: 263-277 [view]
  57. Simon, V., Padte, N., Murray, D., Vanderhoeven, J., Wrin, T., Parkin, N., Di Mascio, M., and Markowitz, M. 2003. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection. J Virol. 77(14): 7736-7745 [view]
  58. Poles, M.A., Barsoum, S., Yu, W., Yu, J., Sun, P., Daly, J., He, T., Mehandru, S., Talal, A., Markowitz, M., Hurley, A., Ho, D., and Zhang, L. 2003. Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood T cells despite suppressive therapy. J Virol.77(19): 10456-10467 [view]
  59. Mehendru, S., and Markowitz, M. 2003. Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection. Expert Opin Investig Drugs. 2003 Nov;12(11):1821-8. [view]
  60. Di Mascio, M., Markowitz, M., Louie, M., Hogan, C., Hurley, A., Chung, C., Ho, D. D., and Perelson, A. S. 2003. Viral blip dynamics during highly active antiretroviral therapy. J Virol. 2003 Nov;77(22):12165-72. [view]
  61. Dixit, N.M., Markowitz, M., Ho, D.D., and Perelson, A.S. 2004. Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy. Antivir. Ther. 9: 237-246 [view]
  62. Leigh Brown, A.J., Frost, S.D., Good, B., Daar, E.S., Simon, V., Markowitz, M., Collier, A.C., Connick, E., Conway, B., Margolick, J.B., Routy, J.P., Corbeil, J., Hellmann, N.S., Richman, D.D., and Little, S.J. 2004. Genetic basis of hypersusceptibility to Protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strain in primary infection. J. Virol. 78(5): 2242-2246 [view]
  63. Mehandru, S., Poles, M.A., Tenner-Racz, K., Horowitz, A., Hurley, A., Hogan, C., Boden, D., Racz, P., and Markowitz, M. 2004. Primary HIV-1 Infection Is Associated with Preferential Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract. J Exp Med. 200(6):761-770. [view]
  64. Di Mascio, M., Markowitz, M., Louie, M., Hurley, A., Hogan, C., Simon, V., Follmann, D., Ho, D.D., and Perelson, A.S. 2004. Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection. J Virol. 78(19):10566-10573 [view]
  65. Mehandru, S, Wrin, T, Galovich J, Stiegler G, Vcelar B, Hurley A, Hogan C, Vasan S, Katinger H, Petropoulos CJ, and Markowitz M. 2004. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J. Virol. 78(24):14039-14042 [view]
  66. Markowitz, M., Hill-Zabala, C., Lang, J., DeJesus, E., Qiming, L., Lanier, E.R., Davis, E.A., and Shaefer, M. for the ESS40013 Study Team. 2004. Induction with Abacavir/Lamivudine/Zidovudine + Efavirenz for 48 Weeks Followed by 48-week Maintenance with Abacavir/Lamivudine/Zidovudine Alone in Antiretroviral Naïve HIV- 1 Infected Patients. JAIDS39(3):257-64. [view]
  67. Di Mascio, M., Percus, J.K., Percus, O.E., Markowitz, M., Ho, D.D., and Perelson, A.S. 2005.  Duration of an Intermittent Episode of Viremia.  Bul. Math. Biol. 67:885-900. [view]
  68. Markowitz, M., Mohri, H., Mehandru, S., Shet, A., Berry, L., Kalyanaraman, R. Kim, A., Chung, C., Jean-Pierre, P., Horowitz, A., La Mar, M., Wrin, T., Parkin, N., Poles, M., Petropoulos, C., Mullen, M., Boden, D., and Ho, D.D.   2005.  Infection With Multi-drug Resistant, Dual-tropic HIV-1 and Rapid Progression of AIDS:  A Case Report. Lancet 365(9464):1031-38. [view]
  69. Mehandru, S., Tenner-Racz, K., Racz, P., and Markowitz, M.  2005. The Gastrointestinal Tract is Critical to the Pathogenesis of Acute HIV-1 Infection.  J of Allergy and Clinical Immunology116: 419-22. [view]
  70. Shet, A., Berry, L., Mohri, H., Mehandru, S., Chung, C., Kim, A., Jean-Pierre, P., Hogan, C., Simon, V., Boden, B. and Markowitz, M. 2006. Tracking the Prevalence of Transmitted Antiretroviral Drug-Resistant HIV-1: A Decade of Experience. JAIDS 41(4):439-46.
  71. Shet, A. and Markowitz, M.  2006.  Transmitted Multidrug Resistant HIV-1:  New and Investigational Therapeutic Approaches.  Curr. Opin in Invest. Drugs 7(8):709-20.
  72. Low A., and Markowitz, M. 2006.  Predictors of Response to Highly Active Antiretroviral Therapy.  AIDS Reader 16:425-37.
  73. Hecht, L.M., Wang, L., Coller, A., Little, S., Markowitz, M., Margolick, J., Kilby, J.M., Daar, E., Conway, B. and Holte, S.  2006.  A Multicenter Observational Study of the Potential Benefits of Initiating Combination Antiretroviral Therapy during Acute HIV-1 Infection.  J Infect. Dis. 194(6):725-33
  74. DeJesus, E., Berger, D., Markowitz, M.,  Cohen, C. Hawkins, T, Ruane, P., Elion, R., Farthing, C. Zhong, L. Cheng, A.K., McColl, D., and Kearney, B.P.  2006. Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naïve and Treatment-Experienced Patients.  JAIDS 43:1-5.
  75. Mehandru, S., Poles, M.A., Tenner-Racz, K., Manuelli, Jean-Pierre, P., Lopez, P., Shet, A., Low, A., Mohri, H., Boden, D., Racz, P., and Markowitz, M.  2006.  Lack of Mucosal Immune Reconstitution during Prolonged Treatment of Acute and Early HIV-1 Infection.  PLoS Med ­3(12):e484.
  76. Markowitz, M., Morales-Ramirez, J.O., Nguyen, B.Y., Kovacs, C.M., Steigbigel, R.T., Cooper, D.A., Loprace, R., Schwartz, R., Isaacs, R., Gilde, L.R., Wenning, L., Zhao, J., Teppler, H., and the Protocol 004 Study Team. 2006. Antiretroviral Activity, Dosed Monotherapy for 10 Days in Treatment-Naive HIV-1 Infected.  JAIDS 43(5):509-515.
  77. Barbour, J.D., Hecht, F.M., Little, S.J., Markowitz, M., Daar, D.S., Kelleher, A.D., Routy, J.P., Campbell, T.B., Rosenberg, E.S., Segal, M.R., Weidler, J., and Grant, R.M.  2006.  Greater CD4 T-cell Gains after One Year of Antiretroviral Therapy are Associated with Lower HIV-1 pol Replication Capacity.  AIDS 20(16):2123-5.
  78. Mehandru, S. Poles, M/A., Tenner- Racz, K., Manuelli, Jean-Pierre, P., Lopez, P., Shet, A., Low, A., Mohri, H., Boden, D., Racz, P., and Markowitz, M.  2006.  Mechanisms of Gastrointestinal CD4+ T Cell Depletion during Acute and Early HIV-1 Infection.  J Virol 81(2):599-612.
  79. Bozzacco, L., Trumpfheller, C., Siegal, F.P., Mehandru, S., Markowitz, M.,Carrington, M., Nussenzweig, M.C., Piperno, A.G., and Steinman, R.M.   2007.   DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes.   PNAS 104(4):1289-94.

 

Reviews/Chapters:
  1. Markowitz, M., Mourandian, J., Moore A. Acute and Chronic Lymphocytic Leukemia. Diseases of the Lymphatic System, ed. Mollander. Springer-Verlag, 1984.

  2. Markowitz, M., Nachman, R. Review of Hematology for Current Medicine, ed. Gitnick, 1986 Year Book Medical Publishers, 261-285.

  3. Markowitz, M. and Ho, D.D. Resistance to Inhibitors of HIV-1 Protease, ed. Richman, D., John Wiley & Sons. 261-279.

  4. Ramratnam, B., and Markowitz, M. Antiretroviral treatment in HIV-1 infected adults. Infection Highlights 1997. Health Press Limited, 1998. 73-80.
  5. Lewin, S.R., and Markowitz, M. 1999. HIV Pathogenesis. In Humes HD (ed.). Kelley's Textbook of Internal Medicine. (in press).

  6. Ramratnam, B., and Markowitz, M. 2001. Kinetics of Human Immunodeficiency Virus Type 1 Replication and Therapy. Antiretoviral Therapy, ed. De Clercq. ASM Press, 1-10.
ADARC home About UsAbout HIV Research ProgramsClinical ProgramsNews & EventsResources Research Labs
ADARC home

The Aaron Diamond AIDS Research Center
455 First Avenue, New York, NY 10016
tel. 212-448-5000   fax 212-725-1126
webinfo@adarc.org | Travel Directions